#United States #New York #Class Action #Gross Law Firm #Organon Co

Overview

The Gross Law Firm has issued a notice regarding a class action lawsuit against Organon & Co. (NYSE: OGN), a pharmaceutical company focused on women's health and other therapeutic areas. This lawsuit is particularly relevant for shareholders who acquired OGN shares during the designated class period from October 31, 2024, to April 30, 2025. Investors who believe they may have been affected by misleading information regarding the company’s financial health and capital allocation strategies are encouraged to take action.

Allegations Made

According to the details outlined in the lawsuit, it is alleged that Organon's management provided overly optimistic statements about the company's performance while intentionally withholding crucial information. Important facts regarding the company's financial priorities, especially concerning capital allocation via quarterly dividends, were reportedly concealed. Notably, the defendants concealed a shift towards a debt reduction strategy that followed Organon’s acquisition of Dermavant. As a result, shareholders experienced a staggering 70% decrease in the regular quarterly dividend.

This revelation led to a significant depreciation in the company's stock price, which dropped more than 27% day-over-day—from a closing price of $12.93 on April 30, 2025, to $9.45 on May 1, 2025. Such drastic fluctuations indicate the potential impact of the alleged misleading statements by the company on its investors.

Important Dates and Deadlines

The firm emphasizes that affected shareholders should not delay in registering for the class action. The critical deadline to file for lead plaintiff status in this lawsuit is July 22, 2025. Interested investors can register directly through the Gross Law Firm's submission form available on their website.

Steps for Shareholders

Once registered as a shareholder who purchased OGN shares during the specified timeframe, individuals will be enrolled in a portfolio monitoring system. This system allows investors to receive continuous updates regarding the status of the case throughout its lifecycle.

Importantly, there is no financial obligation associated with participating in this lawsuit. The firm advises shareholders that while becoming a lead plaintiff is advantageous for one’s role in the case, it is not a requirement for participating in any recovery resulting from the lawsuit.

Why Choose Gross Law Firm?

The Gross Law Firm is regarded as a nationally recognized legal entity specializing in class action cases. Its mission is to advocate for the rights of investors who have been victimized by deceptive practices, fraud, and other unauthorized business conduct. The firm is committed to holding companies accountable and ensuring that they adhere to ethical business practices and good corporate citizenship.

With a proven track record of seeking recovery for investors impacted by false and misleading statements that artificially inflate stock prices, the Gross Law Firm positions itself as a trustworthy ally for affected shareholders. The firm operates with transparency, and no previous outcomes guarantee future results, but their commitment to investor rights remains unwavering.

Contact Information

For further assistance, affected shareholders may contact the Gross Law Firm directly:

• - Address: The Gross Law Firm, 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

Conclusion

As the July 22 deadline approaches, shareholders of Organon & Co. should be vigilant and proactive in safeguarding their rights. Engaging with the Gross Law Firm can provide invaluable insights and support in navigating the complexities of this class action lawsuit, ensuring that investors have the opportunity for potential recovery from their losses.